STOCKWATCH
·
Pharmaceuticals
Quarterly Updates7 May 2026, 09:41 pm

Lupin FY26: PAT Up 62% YoY to ₹53,555 Mn

AI Summary

Lupin Ltd reported its FY2026 and Q4 FY2026 results, with the Board recommending a 900% dividend. FY26 sales reached ₹2,74,875 Mn, a 23.9% increase YoY, and EBITDA grew by 68.6% to ₹92,405 Mn. Q4 FY26 sales were ₹73,919 Mn, up 32.9% YoY, with EBITDA at ₹26,263 Mn, a 90.6% increase YoY. The company's Net Debt stands at ₹-46,358 Mn. Nilesh Gupta, Managing Director, highlighted the strength and resilience of the business across key geographies, particularly in the U.S. and India.

Key Highlights

  • FY26 Sales up 23.9% YoY to ₹2,74,875 Mn; EBITDA up 68.6% to ₹92,405 Mn.
  • Q4 FY26 Sales increased by 32.9% YoY to ₹73,919 Mn; EBITDA up 90.6% to ₹26,263 Mn.
  • Board recommends a dividend of 900%.
  • Net Debt as of March 31, 2026, stands at ₹-46,358 Mn.
  • R&D investment for Q4 FY26 was ₹5,898 Mn (8.0% of sales).
LUPIN
Pharmaceuticals
LUPIN LTD.

Price Impact